González-Martín A, Pothuri B, Vergote I, et al. - In this randomized, double-blind, phase 3 trial, researchers randomly allotted individuals with newly diagnosed advanced ovarian cancer (n = 733) in a 2:1 ratio to receive niraparib or placebo once daily following a response to platinum-based chemotherapy in order to determine the efficiency of niraparib in such patients. Tumors with homologous-recombination deficiency was seen in 373/733 patients. The median progression-free survival was significantly longer in the niraparib group vs placebo group among the individuals in this category. Anemia, thrombocytopenia, and neutropenia, were the most prevalent adverse events of grade 3 or higher. Treatment-related deaths did not occur. Therefore, those who received niraparib had significantly longer progression-free survival in comparison with the placebo among individuals with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, irrespective of the presence or absence of homologous-recombination deficiency.